GLP stands for glucagon-like peptide, a family of hormones produced by the gut. The most clinically important member is GLP-1, a hormone released within minutes of eating that helps the pancreas time insulin release, slows stomach emptying, suppresses glucagon, and signals fullness to the brain. A class of medications called GLP-1 receptor agonists mimics this natural hormone and has reshaped the treatment of type 2 diabetes and obesity over the past decade.
The Natural Role of GLP-1
GLP-1 is secreted by specialized L cells in the lining of the small intestine. When food arrives, these cells release GLP-1 into circulation within 10 to 15 minutes. The hormone acts at several sites simultaneously. In the pancreas, it amplifies the insulin response to glucose — this is the “incretin effect.” It also suppresses glucagon, the hormone that tells the liver to release stored glucose. In the stomach, GLP-1 slows gastric emptying, so food leaves the stomach more gradually. In the brain, it binds receptors that reduce appetite and produce a sense of fullness.
According to NIDDK, this coordinated set of effects explains why GLP-1-based medications have become among the most effective tools for lowering blood glucose and body weight.
GLP-1 Versus Related Hormones
Several gut hormones contribute to the incretin effect. The table below summarizes the key players that come up in discussions of GLP-based therapies.
| Hormone | Full Name | Primary Effects | Related Medications |
|---|---|---|---|
| GLP-1 | Glucagon-like peptide-1 | Stimulates insulin, suppresses glucagon, slows emptying, reduces appetite | Semaglutide, liraglutide, dulaglutide, exenatide |
| GIP | Glucose-dependent insulinotropic polypeptide | Stimulates insulin after meals, affects fat metabolism | Tirzepatide (dual GLP-1/GIP) |
| GLP-2 | Glucagon-like peptide-2 | Promotes gut lining growth | Teduglutide (for short bowel syndrome) |
| Glucagon | Glucagon | Signals liver to release glucose | Emergency hypoglycemia treatment |
| Insulin | Insulin | Moves glucose into cells | Basal and rapid-acting insulins |
Why GLP-1 Matters for Blood Sugar
In people without diabetes, GLP-1 release is robust and well-timed, contributing up to 70 percent of the insulin response after a carbohydrate-rich meal. In type 2 diabetes, GLP-1 release is often blunted and tissues may respond to it less efficiently. That is part of why post-meal glucose climbs higher and takes longer to come down. Restoring or augmenting GLP-1 signaling through medication bypasses the deficit and produces substantial glucose-lowering effects. For a broader look at A1C and glucose regulation, see our A1C levels guide.
GLP-1 Medications at a Glance
GLP-1 receptor agonists are synthetic molecules that activate the GLP-1 receptor the same way the natural hormone does, but with modifications that make them resistant to rapid breakdown. Natural GLP-1 has a half-life of about two minutes; medications like semaglutide last a week. That allows once-weekly or once-daily dosing for meaningful clinical effects.
Currently approved agents for type 2 diabetes include semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon). Semaglutide in higher doses (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management. Tirzepatide (Mounjaro, Zepbound) adds GIP receptor activation for a dual mechanism. A tablet form of semaglutide (Rybelsus) is also available.
What GLP-1 Medications Do
- Lower A1C by approximately 1.0 to 2.0 percentage points in most trials.
- Produce weight loss of 5 to 20 percent depending on agent and dose.
- Reduce major cardiovascular events in trials with high-risk patients.
- Slow progression of kidney disease in some studies.
- Typically cause gastrointestinal side effects during dose escalation.
How to Support Natural GLP-1 Release
Food choices influence GLP-1 secretion. Protein and fiber are the most consistent triggers. Foods with some evidence of boosting GLP-1 include eggs, fish, chicken, lentils, beans, oats, nuts, avocado, and fermented foods such as yogurt and kefir. The effect from diet alone is modest compared with pharmaceuticals, but dietary patterns rich in these foods support overall glucose regulation. Our diet and nutrition hub offers meal ideas aligned with this approach.
Important Caveats About GLP-Based Therapies
GLP-1 medications are prescription-only and carry specific risks. FDA-labeled warnings include thyroid C-cell tumors (based on rodent studies), pancreatitis, gallbladder disease, and acute kidney injury from dehydration. Hypoglycemia risk rises when these drugs are combined with insulin or sulfonylureas. Pregnancy is a contraindication for most. Only a clinician can assess whether a GLP-1 or dual agonist is appropriate, and dosing must come from your prescriber — never improvised.
The Bottom Line
GLP means glucagon-like peptide, and GLP-1 is the gut hormone at the center of modern diabetes and obesity pharmacology. Its natural job is to time insulin release, slow digestion, and signal fullness after meals. Medications that mimic GLP-1 reshape glucose control and body weight for many patients, but they are tools that belong in a clinician-guided plan. Understanding what GLP means is a useful starting point for informed conversations about your options.
